Revolutionising cancer diagnostics
A step change in the detection, diagnosis and monitoring of disease.
Biofidelity’s unique ASPYRE technology enables fast, simple and ultra-sensitive detection of genetic panels from both tissue and liquid biopsies using existing laboratory instrumentation.
ASPYRE-Lung
Comprehensive coverage of NCCN guideline recommended markers for NSCLC
- 111 markers across 11 genes
- 0.1% allele-fraction sensitivity in a simple workflow
- Simultaneous DNA & RNA analysis on one instrument
Latest News
New California Law Increases Access to Biomarker Testing for Late-Stage Cancer Patients
13 October 2021
13 October 2021
Successful alpha testing of Biofidelity’s ASPYRE-Lung reagents demonstrates breakthrough capabilities and ease of use
14 September 2021
14 September 2021
15 July 2021